Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy.

bipolar disorders clozapine depression fronto‐temporal atrophy mixed features oxcarbazepine rivastigmine

Journal

Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 25 06 2019
revised: 07 08 2019
accepted: 12 08 2019
entrez: 5 3 2020
pubmed: 5 3 2020
medline: 5 3 2020
Statut: epublish

Résumé

This paper reports the case of a 46-year-old woman suffering from bipolar disorder of type I with mixed features with initial fronto-temporal atrophy. Although considered treatment-resistant to conventional strategies, she successfully responded to a combination of rivastigmine, clozapine, and oxcarbazepine.

Identifiants

pubmed: 32128167
doi: 10.1002/ccr3.2462
pii: CCR32462
pmc: PMC7044366
doi:

Types de publication

Case Reports

Langues

eng

Pagination

254-257

Informations de copyright

© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

Nothing to declare.

Références

Lancet Psychiatry. 2016 Jun;3(6):502-3
pubmed: 27262046
Ther Adv Psychopharmacol. 2016 Oct;6(5):308-316
pubmed: 27721970
Curr Treat Options Neurol. 2014 Mar;16(3):281
pubmed: 24464490
Trends Neurosci. 2018 Jan;41(1):18-30
pubmed: 29169634
CNS Drugs. 2014 Nov;28(11):989-1003
pubmed: 25160685
Bipolar Disord. 2015 May;17(3):235-47
pubmed: 25346322
Bipolar Disord. 2013 Feb;15(1):1-44
pubmed: 23237061
Epilepsy Res. 2018 Nov;147:119-120
pubmed: 30220619
Harv Rev Psychiatry. 2014 Sep-Oct;22(5):274-94
pubmed: 25188733
BMC Psychiatry. 2010 Sep 07;10:69
pubmed: 20822517
N Engl J Med. 2004 Dec 9;351(24):2509-18
pubmed: 15590953
World J Biol Psychiatry. 2009;10(2):85-116
pubmed: 19347775
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Am J Psychiatry. 2015 Aug 1;172(8):731-42
pubmed: 26085043
Curr Med Chem. 2019;26(38):6942-6969
pubmed: 31385763
Curr Pharm Des. 2016;22(8):949-54
pubmed: 26654774
Clin Case Rep. 2020 Jan 07;8(2):254-257
pubmed: 32128167
J Mov Disord. 2015 May;8(2):98-102
pubmed: 26090082
Consult Pharm. 2006 Jul;21(7):563-75
pubmed: 16934009
Curr Drug Targets. 2013 May 1;14(5):571-7
pubmed: 23531160
Neurosci Biobehav Rev. 2014 May;42:132-47
pubmed: 24603026
Expert Opin Pharmacother. 2019 Aug;20(11):1321-1330
pubmed: 31132287
Int J Neuropsychopharmacol. 2013 Mar;16(2):485-96
pubmed: 22575611
Bipolar Disord. 2012 Dec;14(8):863-9
pubmed: 23107278

Auteurs

Paolo Morana (P)

Casa di cura Morana Marsala Italy.

Federico Mucci (F)

Dipartimento di Medicina Clinica e Sperimentale Section of Psychiatry University of Pisa Italy.

Stefano Baroni (S)

Dipartimento di Medicina Clinica e Sperimentale Section of Psychiatry University of Pisa Italy.

Alessandra Della Vecchia (A)

Dipartimento di Medicina Clinica e Sperimentale Section of Psychiatry University of Pisa Italy.

Armando Piccinni (A)

Brain Research Foundation (BRF) Lucca Italy.
UNICamillus University of health medical sciences Roma Italy.

Benedetto Morana (B)

Casa di cura Morana Marsala Italy.

Donatella Marazziti (D)

Dipartimento di Medicina Clinica e Sperimentale Section of Psychiatry University of Pisa Italy.
Brain Research Foundation (BRF) Lucca Italy.
UNICamillus University of health medical sciences Roma Italy.

Classifications MeSH